Literature DB >> 1330449

Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation.

D A Horak1, G M Schmidt, J A Zaia, J C Niland, C Ahn, S J Forman.   

Abstract

STUDY
OBJECTIVE: To determine the value of pulmonary function tests (PFTs) in predicting the development of human cytomegalovirus (CMV)-associated interstitial pneumonia (IP) in allogeneic bone marrow transplant (BMT) recipients.
DESIGN: Nonrandomized, prospective, open-trial study.
SETTING: Tertiary referral medical center. PATIENTS: 66 evaluable CMV-seropositive patients with hematologic malignancies who were undergoing allogeneic BMT. INTERVENTION: FEV1, FVC, FEV1/FVC, TLC, Dcoc/VA, PaO2, and P(A-a)O2 were measured on days -13, +33, and +44 following BMT. CMV-IP was diagnosed when typical roentgenographic findings developed with confirmatory positive bronchoalveolar lavage (BAL) using standard cytologic and/or rapid culture techniques. MEASUREMENT AND MAIN
RESULTS: Univariate logistic regression analysis to predict the development of CMV-IP revealed significant associations with the day -13 and +33 percent predicted FEV1, FVC, and TLC (p < 0.01) but no associations with other PFT parameters or with changes in these parameters. Stepwise logistic regression analysis demonstrated that only BAL positivity for CMV (odds ratio 14.8; p = 0.0002) and day -13 percent predicted FEV1 (odds ratio 0.92; p = 0.0004) were significant independent predictors of CMV-IP.
CONCLUSION: Pretransplant lung function is a previously unrecognized strong predictor and risk factor for the subsequent development of CMV-IP in BMT recipients.

Entities:  

Mesh:

Year:  1992        PMID: 1330449     DOI: 10.1378/chest.102.5.1484

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation.

Authors:  Tanyalak Parimon; David K Madtes; David H Au; Joan G Clark; Jason W Chien
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

2.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

3.  Alveolar macrophage activity and the pulmonary complications of haematopoietic stem cell transplantation.

Authors:  A T Whittle; M Davis; C L Shovlin; P S Ganly; C Haslett; A P Greening
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Pre-hematopoietic stem cell transplant lung function and pulmonary complications in children.

Authors:  Ashok Srinivasan; Saumini Srinivasan; Sudeep Sunthankar; Anusha Sunkara; Guolian Kang; Dennis C Stokes; Wing Leung
Journal:  Ann Am Thorac Soc       Date:  2014-12

5.  Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children is Associated with Improved Survival.

Authors:  Ashok Srinivasan; Anusha Sunkara; William Mitchell; Sudeep Sunthankar; Guolian Kang; Dennis C Stokes; Saumini Srinivasan
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-01       Impact factor: 5.742

6.  Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes.

Authors:  Alba Ramirez-Sarmiento; Mauricio Orozco-Levi; Eric C Walter; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-23       Impact factor: 5.742

7.  Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?

Authors:  Jason W Chien; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2009-04       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.